Agenus, Inc. (AGEN)
6.94
+0.05
(+0.73%)
USD |
NASDAQ |
Sep 11, 16:00
6.94
0.00 (0.00%)
After-Hours: 20:00
Agenus Enterprise Value : 560.41M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 560.41M |
| September 10, 2026 | 558.28M |
| September 09, 2026 | 557.00M |
| September 08, 2026 | 581.29M |
| September 04, 2026 | 615.81M |
| September 03, 2026 | 615.81M |
| September 02, 2026 | 609.42M |
| September 01, 2026 | 605.16M |
| August 31, 2026 | 588.96M |
| August 28, 2026 | 591.10M |
| August 27, 2026 | 597.49M |
| August 26, 2026 | 616.24M |
| August 25, 2026 | 620.93M |
| August 24, 2026 | 591.52M |
| August 21, 2026 | 609.42M |
| August 20, 2026 | 583.85M |
| August 19, 2026 | 616.66M |
| August 18, 2026 | 585.56M |
| August 17, 2026 | 569.36M |
| August 14, 2026 | 576.61M |
| August 13, 2026 | 562.97M |
| August 12, 2026 | 558.71M |
| August 11, 2026 | 555.72M |
| August 10, 2026 | 562.97M |
| August 07, 2026 | 561.26M |
| Date | Value |
|---|---|
| August 06, 2026 | 583.85M |
| August 05, 2026 | 596.21M |
| August 04, 2026 | 618.37M |
| August 03, 2026 | 597.91M |
| July 31, 2026 | 584.28M |
| July 30, 2026 | 601.75M |
| July 29, 2026 | 547.20M |
| July 28, 2026 | 545.92M |
| July 27, 2026 | 525.89M |
| July 24, 2026 | 519.50M |
| July 23, 2026 | 528.45M |
| July 22, 2026 | 500.32M |
| July 21, 2026 | 502.46M |
| July 20, 2026 | 476.46M |
| July 17, 2026 | 478.16M |
| July 16, 2026 | 477.74M |
| July 15, 2026 | 478.16M |
| July 14, 2026 | 481.15M |
| July 13, 2026 | 525.47M |
| July 10, 2026 | 407.42M |
| July 09, 2026 | 402.73M |
| July 08, 2026 | 403.16M |
| July 07, 2026 | 413.81M |
| July 06, 2026 | 409.98M |
| July 02, 2026 | 413.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novavax, Inc. | 1.131B |
| Amgen, Inc. | 247.31B |
| Anika Therapeutics, Inc. | 266.01M |
| BioCryst Pharmaceuticals, Inc. | 2.556B |
| Imunon, Inc. | 7.840M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.567M |
| Revenue (Quarterly) | 34.52M |
| Total Expenses (Quarterly) | 35.07M |
| EPS Diluted (Quarterly) | -0.0146 |
| Gross Profit Margin (Quarterly) | 98.50% |
| Profit Margin (Quarterly) | -1.64% |
| Earnings Yield | 38.20% |
| Operating Earnings Yield | 13.99% |
| Normalized Earnings Yield | 14.38 |